CD34 is a marker of human HSC, and all colony-forming activity of human bone marrow (BM) cells is found in the CD34+ fraction. Clinical transplantation studies that used enriched CD34+ BM cells indicated the presence of HSC with long-term BM reconstitutional ability within this fraction.

2023年8月10日 · In this article, we will critically review the progress in the delineation of the human postnatal CD34 + HSC–enriched population by examining the methodologies and approaches that have been used over the past 3 decades.

CD34 is predominantly regarded as a marker of hematopoietic stem cells (HSC) and hematopoietic progenitor cells. However, CD34 is now also established as a marker of several other nonhematopoietic cell types, including vascular endothelial progenitors 1 …

CD34 is primarily known as a biomarker for hematopoietic stem cells (HSCs) and hematopoietic stem precursor cells, but it has also been identified as a marker for several non-hematopoietic cells.

2001年1月15日 · Using a competitive long-term reconstitution assay, the results of this study confirm developmental changes in CD34 expression on murine HSC. In fetuses and neonates, CD34 was expressed on Lin − c-Kit + long-term repopulating HSC …

2022年4月19日 · Using various platforms including single cell RNA-sequencing and extensive xenotransplantation, we have uncovered an uncharacterized human CD34+ HSC population.

2023年8月10日 · The ability to isolate and characterize different hematopoietic stem cell (HSC) or progenitor cell populations opens avenues to understand how hematopoiesis is regulated during development, homeostasis, and regeneration as well as in age-related conditions such as clonal hematopoiesis and leukemogen …

In addition to well-characterized CD34 + hematopoietic stem and progenitor cells (HSPCs), the human hematopoietic stem cell (HSC) hierarchy contains a rare CD34 − population with severe combined immunodeficiency-repopulating capacity.

In this review, results on murine and human CD34 (+) and CD34 (-) HSC, differences between them and their possible interactions are examined. Remarkable progress has been achieved in the characterization and isolation of primitive hematopoietic stem cells (HSC).

2020年9月11日 · Purification and targeting of the HSC-enriched CD34+CD90+ subset is less expensive and more efficient with predictable results ex vivo and in vivo. Modifying CD34+CD90+ cells can overcome current roadblocks for the routine clinical use of HSC gene therapy.